Arrowhead Pharmaceuticals prices upsize convertible notes offering to $625M and stock offering at $64.50

Arrowhead Pharmaceuticals (ARWR) announced its public offerings, pricing $625M of 0.00% convertible senior notes due in 2032 and 3.1M shares of common stock at $64.50 per share. Instead of common ...
Nasdaq

Arrowhead price target lowered to $45 from $62 at Piper Sandler

Piper Sandler lowered the firm’s price target on Arrowhead (ARWR) to $45 from $62 and keeps an Overweight rating on the shares. The firm notes Arrowhead entered a strategic partnership with Sarepta ...
Nasdaq

Arrowhead price target raised to $80 from $60 at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the shares after the company recently announced a global license ...
Business Insider

Arrowhead price target lowered to $38 from $51 at B. Riley

B. Riley lowered the firm’s price target on Arrowhead (ARWR) to $38 from $51 and keeps a Buy rating on the shares following the fiscal Q1 report. The firm says Ionis Pharmaceuticals’ (IONS) Tryngolza ...